SCOUT-1
Recruiting
750 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
Phase 2 Recruiting
190 enrolled
A Study of PHST001 in Advanced Solid Tumors
Phase 1 Recruiting
272 enrolled
OCTOPOD-IP
Phase 1 Recruiting
18 enrolled
ENVISION
Recruiting
4,200 enrolled
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
150 enrolled
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
Phase 1 Recruiting
138 enrolled
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Phase 1 Recruiting
63 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 Recruiting
714 enrolled
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
124 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
A Study of SHR-A1811 in Subjects With Ovarian Cancer
Phase 3 Recruiting
300 enrolled
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Phase 4 Recruiting
100 enrolled
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
Phase 3 Recruiting
384 enrolled
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
Phase 1 Recruiting
214 enrolled
TroFuse-020
Phase 3 Recruiting
686 enrolled
TroFuse-033
Phase 3 Recruiting
1,123 enrolled
A Study of LY4175408 in Participants With Advanced Cancer
Phase 1 Recruiting
240 enrolled
OMNIRAY
Phase 1 Recruiting
421 enrolled
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Phase 1/2 Recruiting
245 enrolled
FiREBOLT
Phase 1 Recruiting
241 enrolled
FRAmework-01
Phase 3 Recruiting
1,080 enrolled
TroFuse-036
Phase 3 Recruiting
1,023 enrolled
TroFuse-022
Phase 3 Recruiting
770 enrolled
MAESTRA 2
Phase 3 Recruiting
466 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
TroFuse-021
Phase 3 Recruiting
900 enrolled
DENALI
Phase 2 Recruiting
310 enrolled
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
450 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard Treatments
Phase 1/2 Recruiting
350 enrolled
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
132 enrolled
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer
Phase 3 Recruiting
720 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
OCTOPOD
Phase 1/2 Recruiting
44 enrolled
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Phase 2 Recruiting
140 enrolled
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 Recruiting
270 enrolled
MAESTRA 1
Phase 2 Recruiting
160 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
MRD
Phase 1/2 Recruiting
30 enrolled
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
80 enrolled
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 Recruiting
100 enrolled
OVATION-3
Phase 3 Recruiting
500 enrolled
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Phase 3 Recruiting
700 enrolled
SELECT-2CAR
Phase 1/2 Recruiting
72 enrolled
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Recruiting
595 enrolled